Loading company…
MYR develops treatments for chronic hepatitis B and D infections.
Founded in 2011 by Dmitry Popov and based in Bad Homburg, Germany, MYR develops therapies for chronic hepatitis B and D infections. Its initial product, Bulevitide, is an inhibitor being studied in a Phase 3 trial for chronic HDV. In March 2021, MYR agreed to be fully acquired by Gilead Sciences, Inc.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in